Angiogenesis is regulated by integrin-dependent cell adhesion and the activation of specific cell surface receptors on vascular endothelial cells by angiogenic factors. Lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) are bioactive lysophospholipids that activate G protein -coupled receptors that stimulate phosphatidylinositol 3-kinase (PI3K), Ras, and Rho effector pathways involved in vascular cell survival, proliferation, adhesion, and migration. Previous studies have shown that anastellin, a fragment of the first type III module of fibronectin, functions as an antiangiogenic peptide suppressing tumor growth and metastasis. We have previously shown that anastellin blocks serum-dependent proliferation of microvessel endothelial cells (MVEC) by affecting extracellular signal-regulated kinase (ERK) -dependent G 1 -S transition. However, the mechanism by which anastellin regulates endothelial cell function remains unclear. In the present study, we mapped several lysophospholipid-mediated signaling pathways in MVEC and examined the effects of anastellin on LPA-and S1P-induced MVEC proliferation, migration, and cytoskeletal organization. Both LPA and S1P activated PI3K, Ras/ERK, and Rho/Rho kinase pathways, leading to migration, G 1 -S cell cycle progression, and stress fiber formation, respectively. Stimulation of proliferation by LPA/S1P occurred through a G i -dependent Ras/ERK pathway, which was independent of growth factor receptors and PI3K and Rho/Rho kinase signaling. Although LPA and S1P activated both PI3K/Akt and Ras/ERK signaling through G i , anastellin inhibited only the Ras/ERK pathway. Stress fiber formation in response to LPA was dependent on Rho/Rho kinase but independent of G i and unaffected by anastellin. These results suggest that lysophospholipid mediators of G i activation leading to PI3K/Akt and Ras/ERK signaling bifurcate downstream of G i and that anastellin selectively inhibits the Ras/ERK arm of the pathway. (Mol Cancer Res 2009;7(2):255 -65) 
Introduction
Angiogenesis is controlled by a complex series of coordinated signaling events that are regulated by integrindependent cell adhesion and the activation of specific cell surface receptors on vascular endothelial cells by angiogenic factors. The angiogenic response has both normal and pathologic roles, including tissue repair and regeneration, during wound healing and growth of primary and metastatic tumors. Integrin receptor ligation to an extracellular fibronectin matrix has long been recognized to play a critical role in the regulation of endothelial cell adhesion, migration, proliferation, and survival (reviewed in ref. 1) . Lysophosphatidic acid (LPA) and sphingosine-1 phosphate (S1P) are membrane-derived bioactive lysophospholipids generated from phospholipid precursors of activated platelets, epithelial cells, macrophages, and some cancer cells with reported serum concentrations of 1 to 10 Amol/L and 0.2 to 0.5 Amol/L, respectively (2) . LPA and S1P activate a variety of widely expressed G proteincoupled receptors of the endothelial differentiation gene (Edg) family that regulate a broad range of cellular functions, including survival, proliferation, adhesion, migration, and chemotaxis, suggesting potential roles in inflammation, wound healing, and tumor progression (3) . LPA and S1P receptors couple to at least three distinct G protein subfamilies, including G 12/13 , G q/11 , and G i . Effects of LPA and S1P on cell survival and proliferation have been linked to G i -dependent activation of phosphatidylinositol 3-kinase (PI3K) and Ras effector pathways, whereas activation of the Rho/Rho kinase (ROCK) pathway, implicated in the regulation of cell morphology, adhesion, and migration, has been linked to activation of G 12 / 13 -coupled Edg receptors (4) (5) (6) (7) (8) .
LPA is produced in vivo through the action of autotaxin, an exoenzyme that functions in serum to convert lysophosphatidylcholine into bioactive LPA (9) . Studies using autotaxindeficient mice indicate that autotaxin is a major regulator of plasma LPA levels. Autotaxin-deficient mice exhibit impaired vessel formation, suggesting that LPA production is essential for normal vascular development (10, 11) . LPA regulates the barrier function of the endothelium and also stimulates endothelial cell migration and proliferation (reviewed in ref. 12) . S1P is a proangiogenic factor that regulates endothelial cell proliferation and migration, tubulogenesis, and the homing of bone marrow -derived endothelial cell precursors to sites of neovascularization (reviewed in ref. 13 ). Mice in which S1P receptors have been genetically disrupted exhibit vascular abnormalities, indicating a role for S1P in maturation of the vascular system (14) . In addition, antagonists of S1P and S1P receptors inhibit angiogenesis and tumor progression in mice, confirming a role for S1P in angiogenesis and suggesting that S1P is an important therapeutic target for the treatment of cancer (15, 16) .
Previous studies have shown that anastellin, a COOHterminal fragment of the first type III homology repeat of fibronectin (III 1C ), functions as an antiangiogenic peptide to suppress tumor growth and metastasis in mouse models of human cancer (17, 18) . More recently, we have shown that anastellin blocks serum-dependent proliferation of microvessel endothelial cells (MVEC) by modulating extracellular signalregulated kinase (ERK) -dependent expression of cell cycle regulatory proteins and transition into S phase (19) . However, the mechanism by which anastellin regulates endothelial cell function remains unclear. Although the biological effects of LPA/S1P have been actively investigated over the past several years, surprisingly little is known about the signaling pathways regulated by these molecules in endothelial microvessel cells. In the present study, we mapped several lysophospholipidmediated signal transduction pathways in human dermal MVECs and examined the effects of anastellin on LPA-and S1P-activated signal transduction pathways. Both LPA and S1P activated PI3K/Akt, Ras/ERK, and Rho/ROCK signaling pathways, leading to increases in cell proliferation, migration, and stress fiber formation. Endothelial cell transition into S phase by LPA/S1P occurred through a G i -dependent activation of ERK, which was independent of growth factor receptor and PI3K/Akt and Rho/ROCK signaling pathways. Although LPA and S1P activated both PI3K/Akt and Ras/ERK pathways through G i , anastellin specifically inhibited only the Ras/ERK pathway. These results suggest that the G i effector pathways leading to activation of PI3K/Akt and ERK bifurcate downstream of G i and that anastellin selectively inhibits the Ras/mitogen-activated protein/ERK kinase (MEK)/ERK arm of the pathway.
Results

LPA and S1P Stimulate ERK-Dependent [ 3 H]Thymidine Uptake by Microvessel Cells
To examine the ability of LPA and S1P to stimulate proliferation of MVECs, serum-starved MVECs were treated with increasing concentrations of either LPA or S1P and assayed for incorporation of [ 3 H]thymidine. As shown in Fig. 1 , both LPA and S1P treatment resulted in a 3-to 4-fold stimulation of [ 3 H]thymidine incorporation. The induction of cell proliferation by LPA and S1P was accompanied by an increase in the activation of ERK (Supplementary Fig. S1 ). ERK activation was observed in as little as 2.5 minutes and reached maximal stimulation within 5 to 10 minutes of lysophospholipid addition ( Supplementary Fig. S1A and B) . ERK phosphorylation decreased within 30 minutes and was nearly undetectable 60 minutes following addition. LPA activation of ERK was dose dependent between 2.5 and 40 Amol/L (Supplementary Fig. S1C ). Maximum activation of ERK with S1P was seen at 0.5 Amol/L (Supplementary Fig. S1D ). The increases in ERK phosphorylation correlated well with the changes in thymidine incorporation observed in Fig. 1 , suggesting that ERK activation plays a role in lysophospholipidmediated endothelial transition into S phase.
To test whether ERK activation is required for the effects of lysophospholipids on cell growth, MVECs were treated with MEK inhibitors PD98059 or U0126 before LPA or S1P stimulation and examined for effects on [ 3 H]thymidine incorporation. As shown in Fig. 1C and Supplementary Fig. S2A , both MEK inhibitors blocked lysophospholipid-mediated [ 3 H]thymidine incorporation at concentrations similar to those required to block ERK activation ( Fig. 1D ; Supplementary  Fig. S2B ). These data indicate that MEK-dependent ERK activation is required for the S1P/LPA-mediated stimulation of [ 3 H]thymidine uptake by MVECs.
LPA and S1P exert their effects by binding to a diverse group of cell surface G protein -coupled receptors, thereby leading to activation of a variety of downstream signaling events. To evaluate the role of G i in LPA-and S1P-stimulated ERK activation in MVECs, cells were preincubated with increasing concentrations of pertussis toxin (PTx), a G i protein inhibitor. As shown in Supplementary Fig. S3A , as little as 0.1 ng/mL PTx blocked both LPA-and S1P-mediated ERK activation. Control experiments showed that PTx had no effect on ERK activation by either vascular endothelial growth factor (VEGF) or epidermal growth factor (EGF; data not shown). Similarly, PTx treatment completely blocked the ability of LPA to stimulate [ 
Lysophospholipid-Mediated ERK Activation in MVECs Does Not Require EGF or VEGF Receptor Transactivation
Previous studies have shown that activation of the ERK signaling pathway by LPA can occur through a mechanism that involves transactivation of EGF receptor (EGFR) or plateletderived growth factor receptor (20, 21) . Similarly, another report has shown that S1P can activate ERK through transactivation of the VEGF receptor (VEGFR; ref. 22 ). To determine if growth factor receptor transactivation is required for LPA or S1P activation of ERK, MVECs were treated with inhibitors of EGFR and VEGFR kinase activity. As observed in Supplementary Fig. S4A , addition of LPA, S1P, and EGF each stimulated ERK activation. However, only EGF-mediated ERK activation was inhibited by the EGFR inhibitor AG1478, suggesting that LPA and S1P activation of ERK does not involve EGFR kinase activity. This concept was examined further by evaluating the effect of LPA on EGFR phosphorylation. In Supplementary Fig. S4B , MVECs were treated with AG1478 before stimulation with either LPA or EGF. Whereas EGF led to a significant increase in AG1478-sensitive EGFR phosphorylation, LPA treatment resulted in no detectable increase in EGFR phosphorylation. Similarly, we examined the role of VEGFR transactivation in LPA-and S1P-mediated ERK activation. MVECs were treated with the VEGFR inhibitor SU5416 followed by addition of LPA, S1P, and VEGF. As shown in Supplementary Fig. S4C , addition of each led to a robust increase in ERK phosphorylation. Only VEGF activation of ERK was inhibited by treatment with SU5416. Additionally, MVECs treated with LPA resulted in no detectable increase in VEGFR phosphorylation, whereas VEGF was able to stimulate SU5416-inhibitable VEGFR tyrosine phosphorylation ( Supplementary Fig. S4D ). Similar results were seen using an inhibitor (AG1295) of platelet-derived growth factor receptor kinases, which had no effect on activation of ERK by either LPA or S1P (data not shown). Taken together, these data indicate that activation of ERK by LPA or S1P does not require transactivation of these growth factor receptor tyrosine kinases.
Lysophospholipid-Mediated Akt but not ERK Activation Depends on PI3K
Earlier studies have shown that lysophospholipids can activate PI3K/Akt survival pathways in endothelial cells (23, 24) . To determine if lysophospholipids activate Akt in MVECs, cells treated with LPA and S1P were examined for phospho-Akt by Western blot analysis. As shown in Supplementary Fig. S5A and B, both LPA and S1P enhanced phosphorylation of Akt at Ser 473 within 2.5 to 5 minutes of treatment. The kinetics of Akt phosphorylation paralleled those of ERK phosphorylation, peaking between 5 and 10 minutes and returning to basal levels within 60 minutes. To determine whether Akt phosphorylation depended on PI3K activity, MVECs were treated with the PI3K inhibitor LY294002 for 30 minutes before LPA and S1P stimulation. PI3K inhibition completely blocked the ability of both LPA and S1P to stimulate Akt phosphorylation at Ser 473 but had no effect on ERK activation ( Supplementary Fig. S5C ). These results suggest that lysophospholipid-mediated Akt activation in microvessel cells occurs through a PI3K-dependent signaling mechanism, whereas ERK activation is independent of PI3K activity. To determine which G protein family member is required for PI3K/Akt activation, cells were treated with PTx ( Supplementary Fig. S5D ). These data show that PTx blocked both Akt and ERK activation, indicating that S1P/LPA activation of both Akt and ERK occurs through a G idependent signaling pathway.
Effects of Rho/ROCK Signaling on LysophospholipidMediated ERK Activation
Previous studies have shown that LPA is a strong inducer of Rho-dependent signaling pathways in many cell types and plays a central role in cell adhesion, migration, and cytoskeletal organization. Incubation of MVECs with either LPA or S1P resulted in an increase in phospho-Ser 19 myosin light chain 2 (pMLC2), a downstream effector of Rho/ROCK signaling ( Fig.  2A ). These data suggest that both lysophospholipids activate Rho signaling in microvessel cells; however, the effects were more pronounced in LPA-treated cells. To test whether LPA signaling to Rho occurred through a G i -dependent mechanism, MVECs were treated with PTx overnight, stimulated with LPA or S1P, and assessed for changes in MLC2 phosphorylation levels (Fig. 2B) . As shown previously, PTx treatment completely blocked LPA-and S1P-mediated Akt and ERK activation. However, PTx had no effect on the ability of LPA or S1P to stimulate MLC2 phosphorylation, indicating that phospholipid-mediated Rho signaling proceeds through a G iindependent mechanism (Fig. 2B) . To determine the relationship of ERK activation to Rho signaling, MVECs were treated with either the ROCK inhibitor Y27632 or the MEK inhibitor U0126 before LPA or S1P stimulation. As shown in Fig. 2C , the ROCK inhibitor completely blocked the ability of LPA or S1P to phosphorylate MLC2, whereas the PI3K/Akt and MEK/ ERK signaling pathways were unaffected. In addition, inhibition of MEK with U0126 had no effect on either the PI3K/Akt or Rho/ROCK signaling pathways. In support of these data, C3 exoenzyme, a Rho inhibitor, had no effect on the ability of LPA to activate ERK (data not shown). These data indicate that the activation of ERK by LPA does not depend on Rho signaling pathways. Furthermore, the data show that ERK activation is not required for lysophospholipid activation of either Akt or Rho/Rho kinase, suggesting that in microvessel cells, the PI3K/Akt, MEK/ERK, and Rho/ROCK pathways are not interdependent.
Anastellin (III 1C ) Works Upstream of Ras to Block
Lysophospholipid-Mediated ERK Activation and Transition to S Phase To determine whether anastellin can alter lysophospholipid receptor signaling pathways, MVECs were treated with various concentrations of anastellin before LPA and S1P stimulation.
As shown in Fig. 3A , anastellin reduced basal levels of phosphorylated ERK and blocked activation of ERK by LPA and S1P. The effects of anastellin on ERK activation were dose dependent and seen with as little as 5 Amol/L and reaching maximal inhibition at 20 Amol/L anastellin. The control fibronectin module (III 13 ) had no effect on LPA or S1P activation of ERK. The effect of anastellin on ERK activation was seen within 10 minutes with nearly a complete loss of active ERK at 60 minutes (Fig. 3B ). As shown in Fig. 3C , anastellin blocked LPA-or S1P-mediated [ 3 H]thymidine uptake at concentrations similar to those required to block mitogen-activated protein kinase signaling.
To show a role for Ras in the activation of ERK by LPA/S1P, Ras activity was inhibited using an adenoviral construct of dominant-negative RasN17. Figure 4A shows that ERK activation in response to either LPA or S1P was completely attenuated in cells expressing RasN17. In contrast, Akt activation by LPA or S1P was unaffected by RasN17 expression, suggesting that Akt activation was not dependent on Ras. EGF-stimulated concentrations of LPA and S1P as indicated for 6 min were subjected to SDS-PAGE followed by immunodetection with antibodies directed against pMLC2, pS473Akt, and pERK. Alternatively, cells were treated with 1 ng/mL PTx for 20 h (B), 2 Amol/L Y27632, a specific inhibitor of Rho-associated kinase (ROCK), or 5 Amol/L U0126 for 30 min (C) before stimulation with 40 Amol/L LPA or 4 Amol/L S1P for 6 min. Cell extracts were subjected to SDS-PAGE and immunoblots were probed as described above. Membranes were stripped and reprobed with an anti-ERK2 antibody.
ERK activation was also completely attenuated in RasN17-infected cells (data not shown). In contrast, there was no effect on either Akt or ERK activation in response to LPA or S1P stimulation in cells infected with control virus (adenovirus expressing green fluorescent protein alone).
To determine whether anastellin alters lysophospholipidmediated Ras activation, anastellin-treated MVECs were stimulated with LPA and S1P and examined for changes in active Ras using a Ras-GTPase ELISA assay. EGF served as a positive control. LPA induced a significant increase in Ras activation; however, S1P did not increase Ras activity when compared with control cells (Fig. 4B) . As shown in Fig. 4B , anastellin blocked the ability of LPA to induce Ras activation. Conversely, anastellin had no significant effect on EGFstimulated Ras activation, which was consistent with control experiments showing that anastellin did not inhibit the activation of ERK by EGF (data not shown). These data indicate that the activation of ERK by LPA/S1P is dependent on Ras activity and that the inhibitory effect of anastellin on ERK lies upstream of Ras.
Effects of Anastellin on Rho/ROCK Signaling and Cytoskeletal Organization
To determine the effects of anastellin on lysophospholipid signaling through Rho, MVECs were treated with 20 Amol/L anastellin or the control module III 13 before stimulation with LPA and S1P. Cell lysates were immunoblotted for anastellinmediated effects on LPA-induced phosphorylation of ERK, Akt, and MLC2. Although anastellin treatment effectively blocked ERK activation, anastellin had no effect on S1P-or LPA-mediated phosphorylation of either Akt or MLC2 (Fig. 5A) . These results suggest that anastellin does not interfere with the ability of S1P or LPA to initiate downstream signaling to both Rho/ROCK and PI3K/Akt signaling pathways. Rho pull-down assays confirmed that anastellin had no effect on the ability of LPA to activate Rho (data not shown).
We also examined the effects of LPA and S1P on the formation of stress fibers in confluent monolayers of endothelial cells (Fig. 5B) . LPA stimulation dramatically induced the polymerization of actin into cortical stress fibers when compared with control cells (Fig. 5B, arrows) and enhanced immunodetection of pMLC2, consistent with the biochemical data presented in Figs. 2 and 5A. The increase in pMLC2 was predominantly associated with its colocalization to the newly organized cortical stress fibers following LPA stimulation (Fig. 5B, arrowheads and merge) . S1P had little effect on stress fiber formation (data not shown), consistent with earlier results showing that S1P only weakly activated Rho/ROCK signaling (Fig. 2) . Inhibition of Rho kinase with Y27632 dramatically reduced immunodetection of pMLC2 and blocked the formation of cortical stress fibers following LPA stimulation. Moreover, anastellin had no effect on the ability of LPA to induce stress fiber formation or MLC2 phosphorylation (Fig. 5B) . These results are consistent with the data presented in Figs. 2C and 5A and indicate that LPA activation of Rho/ ROCK signaling leading to increased stress fiber formation is not affected by anastellin.
PI3K Signaling Plays a Role in Lysophospholipid-Mediated Endothelial Cell Migration
To determine whether lysophospholipid signaling through Ras/ERK, PI3K/Akt, or Rho/ROCK plays any role in cell migration, endothelial cells were seeded onto collagen-coated Transwell tissue culture inserts and stimulated with LPA or S1P. As shown in Fig. 6A , both lipids increased endothelial cell migration, although S1P was a more potent stimulator than LPA. Migration was PTx sensitive, suggesting that G i activation is required (Fig. 6B ). Cells pretreated with the ROCK inhibitor Y27632 or the MEK inhibitor U0126, before stimulation with LPA or S1P, exhibited no significant changes in migration ( Fig. 6C and D, respectively) , indicating that neither the Rho pathway nor the ERK pathway was required for LPA/ S1P-induced migration. Conversely, LY294002 significantly reduced migration, suggesting a role for PI3K signaling in endothelial cell migration (Fig. 6E) . Similar results were obtained with the PI3K inhibitor wortmannin (data not shown). To determine whether PI3K-mediated Akt activation was specifically required for migration, cells were treated with an Akt-selective inhibitor before stimulation with LPA and S1P. Although lysophospholipid-dependent phosphorylation of Akt was completely blocked (data not shown), migration was unaffected (Fig. 6E) , suggesting that G i -dependent activation of PI3K is required for lysophospholipid-mediated endothelial cell migration, whereas subsequent activation of Akt by PI3K is not. Anastellin had no significant effect on migration in response to LPA/S1P (Fig. 6F) .
As shown in the schematic (Fig. 7) , our results indicate that LPA/S1P activates both PI3K/Akt and ERK signaling through G i -dependent pathways. Activation of Akt but not ERK required PI3K, suggesting that the ERK and Akt signaling pathways are independent. This was confirmed by studies showing that inhibitors of MEK and Ras blocked ERK phosphorylation but did not block Akt phosphorylation. Activation of PI3K led to an increase in cell migration, whereas ERK activation stimulated cell cycle progression. Anastellin had no effect on cell migration but completely inhibited cell proliferation. LPA and S1P (but to a lesser extent) activated the Rho signaling pathway, resulting in the phosphorylation of MLC2 and formation of stress fibers. This pathway was not dependent on G i and did not affect the activation of either ERK or Akt. Activation of Rho by LPA resulted in an increase in stress fibers, which was unaffected by anastellin. These results suggest that the LPA/S1P signaling pathway initiated through G i bifurcates downstream of G i and that anastellin specifically inhibits the Ras/ERK arm of the pathway. The data further indicate that the site of anastellin action lies upstream of Ras but downstream of G i .
Discussion
Anastellin, a peptide derived from the first type III domain of fibronectin, has been shown to exhibit antiangiogenic properties in vivo and to block serum-dependent growth of endothelial cells in vitro (19, 18, 25) . Several studies have documented multiple cellular effects of anastellin, including changes in cell signaling pathways, reorganization of actin filaments, and conformational changes in extracellular fibronectin fibrils (26) (27) (28) . In the present study, we address the mechanism by which anastellin might regulate the angiogenic phenotype. We show that anastellin inhibits signaling pathways initiated by both LPA and S1P, two bioactive phospholipids that have been implicated in the regulation of vascular development and angiogenesis (29, 30) . Our studies indicate that in human MVECs, LPA and S1P regulate similar parallel pathways leading to the activation of ERK, Akt, and Rho kinase and that anastellin is a selective inhibitor of the pathway leading to ERK activation.
Both S1P and LPA bind to members of the Edg family of G protein -coupled receptors to affect several aspects of The effect of anastellin on Ras activation by LPA, S1P, and EGF was examined by active Ras ELISA as described in Materials and Methods. Statistical differences were measured by comparison with the untreated control cells (a) or with stimulated cells in the absence of III 1C . *, P < 0.05; **, P < 0.01; ***, P < 0.001. endothelial cell biology, including proliferation, migration, survival, and barrier function (reviewed in ref. 12). Our data indicate that LPA and S1P can stimulate ERK-dependent [ 3 H]thymidine incorporation in endothelial microvessel cells. Activation of ERK by lysophospholipids is Ras dependent and required for the movement of cells from G 1 into S phase. In several cell types, activation of ERK by LPA or S1P has been linked to transactivation of growth factor receptors or to Rho signaling (22, (31) (32) (33) . We found no evidence to support a role for either growth factor receptors or Rho in the activation of ERK by LPA/S1P in human microvessel cells.
In agreement with this, anastellin had no effect on LPAinduced stress fiber formation, which was dependent on Rho kinase activity. LPA and S1P both stimulated cell migration, which was dependent on PI3K. Although both LPA and S1P stimulated phosphorylation on Akt by PI3K, Akt was not required for cell migration. This suggests that PI3K pathway bifurcates downstream into separate pathways regulating migration and other Akt-dependent pathways, such as cell survival. Anastellin had no effect on cell migration or Akt activation, suggesting that the antiangiogenic activity of anastellin does not result from effect of anastellin on migration or survival.
Activation of both ERK and Akt by LPA/S1P was inhibited by PTx, indicating a role for G i in the LPA/S1P signaling pathways. Although both ERK and Akt lie downstream of G i , anastellin inhibits only the activation of ERK, suggesting that anastellin acts on one arm of a signaling pathway that bifurcates downstream of G i . These data suggest that anastellin selectively inhibits only those biological effects that lie downstream of ERK, such as cell proliferation, without affecting other lysophospholipid-regulated activities, such as migration, survival, endothelial nitric oxide synthase activity, or endothelial barrier function, which lie downstream of PI3K, Akt, or Rho kinase (34) (35) (36) (37) .
Several studies have shown fragments of extracellular matrix molecules to be fairly potent regulators of angiogenesis. These endogenous angiogenic regulators may be presented to the cell either as matrix-derived fragments released through proteolysis or as unfolded cryptic domains that become exposed following changes in the organization of the extracellular matrix (38, 39) . Steered molecular dynamics and nuclear magnetic resonance have shown that the fibronectin III-1 domain unfolds in response to cellular tension to a mechanically stable intermediate, which is similar to the structure of anastellin (40) . Therefore, anastellin may regulate endothelial cell behavior by reproducing the biological effects of conformationally regulated sequences within matrix fibronectin. Alternatively, anastellin may mimic the effects of soluble peptides containing the III-1 domain of fibronectin. Truncated forms of fibronectin that contain the III-1 domain are synthesized by both tumors and tumor-associated stromal cells (41) .
The molecular basis for the antiangiogenic action of anastellin is not well understood. One possibility is that anastellin A. Cells were lysed and extracts were subjected to SDS-PAGE followed by immunodetection with antibodies directed against pMLC2, pS473Akt, and pERK. Membranes were stripped and reprobed with an anti-ERK2 antibody. B. competes for cellular receptors that interact with the III-1 domain present in matrix fibronectin. Earlier studies have shown that h 1 integrin and proteoglycans mediate adhesion of smooth muscle cells to substrate-attached anastellin, which results in the activation of ERK (27) . Additionally, our previous studies have shown that anastellin binds to matrix fibronectin causing conformational changes in the EDA domain (28) , suggesting that anastellin may affect the association of a 4 h 1 integrins with the EDA-containing fibronectin present in matrix (42, 43) . Anastellin-induced changes in fibronectin matrix organization may also regulate VEGF activity, as recent studies have shown that VEGF binds to conformationally labile sites present in the fibronectin matrix (44, 45) . In addition to its effects on angiogenesis, anastellin might exert antitumor effects by regulating lysophospholipid signaling in the tumor cell. LPA autocrine loops have been described in several tumor types (46) (47) (48) . LPA present in ascites fluid contributes to the progression of both ovarian and pancreatic cancers (49, 50) . It is also possible that anastellin may have direct effects on other cell types present in the tumor microenvironment, as earlier studies have shown that anastellin regulates p38 mitogen-activated protein kinase and Cdc42 activity in dermal fibroblasts (26, 28) .
Anastellin triggers polymerization of soluble fibronectin into higher-order polymers termed ''superfibronectin'' (51). Superfibronectin exhibits distinct effects on cell behavior and seems to be important in mediating the antiangiogenic effects of anastellin (52) . Numerous studies have indicated neosynthesis of fibronectin isoforms during tumor progression, and these isoforms are currently being evaluated as targets for tumor therapy (reviewed in ref. 53 ). Angiogenesis associated with solid tumor progression is marked by the presence of alternatively spliced forms of fibronectin, which contain extra type III modules, EDA and EDB (54) (55) (56) , and in vivo studies have shown the fibronectin matrix to be a critical component of angiogenic programs (57) (58) (59) (60) . The specific functions of these isoforms are not well understood, but recent studies have shown that deletion of the EDA/EDB modules from fibronectin results in embryonic lethality due to multiple cardiovascular defects, which include defects in vascular remodeling and angiogenesis (61) . These findings provide compelling evidence that the EDA/EDB isoforms of fibronectin are necessary for appropriate vascular remodeling and suggest that the polymerizing fibronectin matrix may be a useful target for therapeutic modalities directed at controlling tumor progression.
Materials and Methods
Reagents
Unless indicated otherwise, reagents were obtained from Sigma-Aldrich Co. Fetal bovine serum (FBS) was from Hyclone. LPA and tyrphostin AG1478 were obtained from Biomol Research Laboratories. Rabbit polyclonal antibodies to ERK2 and Flk-1 (VEGFR-2) were obtained from Santa Cruz Biotechnology, Inc. Monoclonal antibody to phospho-ERK (pERK), pMLC2, and the MEK inhibitors U0126 and PD98059 were obtained from Cell Signaling Technology. Monoclonal antibody to phosphotyrosine (clone 4G10) was obtained from Upstate Biotechnology. Alexa Fluor 594 phalloidin and monoclonal antibody to pS473Akt were obtained from Invitrogen. The Akt-selective inhibitor VIII (AktI-1/2), PTx, SU5416, LY294002, and Y27632 were obtained from Calbiochem. Vitrogen-100 (type I collagen) was from Cohesion Technologies. Recombinant human VEGF and EGF were obtained from R&D Systems. Recombinant fragments of human fibronectin, III 1C (anastellin) and III 13 , were generated and purified as previously described (28) . Adenovirus expressing dominant-negative RasN17 was a generous gift of Dr. Kevin Pumiglia (Albany Medical College, Albany, NY). The green fluorescent protein adenovirus used as control was obtained from Q-Biogene.
Cell Culture
Human dermal MVECs were obtained from VEC Technologies, Inc. Endothelial cells were cultured in complete medium [MCDB-131, 20% defined FBS, 2 mmol/L GlutaMAX (Life Technologies), and EGM-2MV (Cambrex Corp.)] supplemented with 10 Ag/mL heparin and cultured in a humidified incubator at 37jC/5% CO 2 on collagen-coated (20 Ag/mL) tissue culture dishes. For most experiments, endothelial cells were plated onto collagen-coated dishes in complete medium at a density of 8 Â 10 4 per well (12-well tissue culture dish), cultured overnight, and serum starved in MCDB-131, 0.5% bovine serum albumin (BSA) for 24 h before treatment.
Immunoblot and Expression Analysis
Cell layers were washed twice with ice-cold PBS containing 1 mmol/L Na 3 VO 4 before solubilization in radioimmunoprecipitation assay buffer [20 mmol/L Tris-Cl (pH 7.4), 1% Triton X-100, 0.5% NP40, 0.1 mol/L NaCl, 40 mmol/L NaF, 30 mmol/L Na 4 P 2 O 7 , 2 mmol/L EGTA, 1 mmol/L Na 3 VO 4 , and 0.5 mmol/L phenylmethylsulfonyl fluoride containing Complete Mini protease inhibitors (Roche Biochemical)]. Cell lysates were cleared by centrifugation (14,000 rpm for 10 min at 4jC) and stored at À80jC until use. Protein concentrations were determined with a bicinchoninic acid protein assay reagent kit (Pierce) using BSA as standard. In some experiments, whole-cell lysates were prepared. Briefly, cell layers were first washed thrice with ice-cold PBS containing 1 mmol/L Na 3 VO 4 followed by solubilization in Laemmli buffer. Samples were separated on SDS polyacrylamide gels, transferred onto nitrocellulose membranes (Schleicher & Schuell Bioscience), blocked overnight in TBST [Tris-Cl (pH 7.4), 150 mmol/L NaCl, 0.1% Tween 20] containing 5% (w/v) BSA, and hybridized with primary antibodies. Bound antibodies were hybridized with horseradish peroxidase -conjugated secondary antibodies and detected using an enhanced chemiluminescence reagent (Amersham Biosciences). Blots were reprobed after stripping in 62.5 mmol/L Tris-Cl (pH 6.7) and 2% SDS containing 10 mmol/L h-mercaptoethanol for 30 min at 60jC.
Measurement of DNA Synthesis
MVECs were plated onto collagen-coated 24-well dishes at 1.25 Â 10 4 per well in the presence of complete medium and allowed to adhere overnight. Cells were serum starved for 30 h and treated with various pharmacologic agents as indicated before stimulation with either 20 Amol/L LPA or 2 Amol/L S1P for an additional 16 h. S-phase nuclei were labeled by incubating cells with 1 ACi of [ 
Ras Activation Assays
MVECs were plated onto collagen-coated 10-cm dishes (Ras pull-down) or 60-mm dishes (Ras activity) at a density of 1 Â 10 4 /cm 2 in complete medium and allowed to adhere overnight. Cells were then serum starved for 20 h before addition LPA and S1P activate specific G protein -coupled receptors (LPA 1-4 and S1P [1] [2] [3] [4] [5] , respectively) and initiate Ras/ERK, PI3K/Akt, and Rho/ROCK signaling pathways in MVECs. Results presented here have shown that both Ras/ERK and PI3K/Akt signaling are mediated by a G i -dependent pathway, whereas Rho signaling occurs through an alternate G protein, possibly G 12/13 or G q , as has been shown in previous studies (4) (5) (6) (7) (8) . In addition, G i -dependent activation of Ras/ERK and PI3K/Akt occurs through independent pathways and is unaffected by inhibition of Rho signaling. These results are further supported by the finding that anastellin suppresses Ras activation by LPA and prevents ERK activation without affecting PI3K/Akt or Rho/ROCK signaling. The dashed line linking S1P receptors to G 12/13 indicates that a weak induction by S1P was observed in MVECs.
of 40 mmol/L LPA, 4 mmol/L S1P, or 10 ng/mL EGF for 3 min. Precipitation of activated Ras (Ras-GTP) was carried out using EZ-Detect Ras Activation kit (Pierce) according to the manufacturer's protocol. Alternatively, active Ras was measured using a Ras GTPase Chemiluminescent ELISA kit (Active Motif).
Fluorescence Microscopy
MVECs were cultured overnight on collagen-coated (20 Ag/mL) glass coverslips, serum starved for 4 h (2% FBS, MCDB-131), and treated for 30 min with 2 Amol/L Y27632 or 60 min with 20 Amol/L anastellin before 1-h stimulation with 20 Amol/L LPA or 1 Amol/L S1P. Cells were fixed for 20 min in 3% paraformaldehyde, permeabilized in 0.5% Triton X-100 for 10 min, blocked in 1% BSA, and immunostained with polyclonal antibodies to pMLC2. Filamentous actin was visualized with Alexa Fluor 594 -conjugated phalloidin. Cell layers were examined using an Olympus BMX-60 microscope equipped with a cooled charge-coupled device sensi-camera (Cooke) and images were acquired using Slidebook software (Intelligent Imaging Innovation).
Cell Migration
Transwell tissue culture inserts (6.5 mm diameter, 8.0 Am pore size; Costar) were coated with 20 Ag/mL collagen for 1 h at 37jC, rinsed once, and blocked with 1% BSA. Microvessel cells were trypsinized, washed once, and suspended in MCDB-131 containing 0.2% fatty acid -free BSA, treated with inhibitors for 30 to 60 min at 37jC, and seeded at 5 Â 10 5 per insert. Tissue culture inserts were then placed into wells containing 20 Amol/L LPA or 1 Amol/L S1P with inhibitor concentrations matching that of the inner well. After 4 h, cells were fixed in 3.7% paraformaldehyde, PBS for 15 min and stained with 0.5% crystal violet. Nonmigratory cells attached to the top surface were removed with a cotton tip applicator. Migratory cells adhered to the bottom surface were permeabilized with 0.1% Triton X-100, PBS for 15 min and stained with Hoechst 33258 (1 Ag/mL for 20 min). Cell nuclei were visualized with a fluorescence microscope and three random fields (Â10 magnification) were collected. The average cell number per field was determined by automated counting using ImageJ imaging software.
Data Analysis
Unless indicated otherwise, results are presented as the mean F SE of at least three independent experiments done in duplicate or triplicate. Statistical significance was determined by one-way ANOVA; P values of <0.05 were considered significant.
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